GENinCode (LON:GENI) Reaches New 52-Week Low – Time to Sell?

GENinCode Plc (LON:GENI) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 0.76 and last traded at GBX 0.80, with a volume of 5847561 shares. The stock had previously closed at GBX 0.85.

GENinCode Stock Down 6.5%

The firm’s 50-day moving average price is GBX 1 and its two-hundred day moving average price is GBX 1.24. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The firm has a market cap of £5.99 million, a PE ratio of -0.38 and a beta of 0.59.

GENinCode (LON:GENI) last posted its earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The company had revenue of GBX 308 million during the quarter. As a group, equities research analysts expect that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.